Dr. Noah M. Hahn, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1650 Orleans St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 200
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D77604 -
Medical Oncology Physician
DC license MD046054
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Sibley Memorial Hospital Washington, DC
Medical groups
- Johns Hopkins University (2,909 clinicians)
- Johns Hopkins University (197 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 200
- Services billed
- 76,087
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 29,280 | 11 |
| Injection, ondansetron hydrochloride, per 1 mg | 484 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 251 | 135 |
| Administration of chemotherapy into vein, 1 hour or less | 128 | 25 |
| Established patient office or other outpatient visit, 40-54 minutes | 115 | 52 |
| Infusion into a vein for hydration, each additional hour | 72 | 11 |
| Infusion, normal saline solution , 1000 cc | 69 | 11 |
| Injection of additional new drug or substance into vein | 63 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Baltimore, MD | 26 |
| Oxycodone Hcl Other prescribers in Baltimore, MD | 17 |
| Prednisone Other prescribers in Baltimore, MD | 14 |
| Oxycontin (oxycodone hcl) Other prescribers in Baltimore, MD | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 17 payments worth $18,772 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $9,538 |
|---|---|
| Pfizer Inc. | $6,134 |
| Astellas Pharma US Inc | $2,238 |
| Merck Sharp & Dohme LLC | $610 |
| AstraZeneca UK Limited | $117 |
| Janssen Biotech, Inc. | $115 |
| Gilead Sciences, Inc. | $20.86 |
| Consulting Fee | $18,323 |
|---|---|
| Food and Beverage | $450 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 14, 2025 | Consulting Fee PADCEV · ONCOLOGY | $4,200 |
| AstraZeneca Pharmaceuticals LP Mar 11, 2025 | Consulting Fee | $2,460 |
| Astellas Pharma US Inc Dec 3, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee IMFINZI · Oncology | $2,050 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,875 |
| AstraZeneca Pharmaceuticals LP Jul 10, 2025 | Consulting Fee | $1,370 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee | $1,330 |
| AstraZeneca Pharmaceuticals LP Oct 29, 2025 | Consulting Fee IMFINZI · Oncology | $998 |
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee IMFINZI · Oncology | $665 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 3, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee IMFINZI · Oncology | $665 |
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee IMFINZI · Oncology | $333 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,875 |
| AstraZeneca Pharmaceuticals LP Oct 29, 2025 | Consulting Fee IMFINZI · Oncology | $998 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee IMFINZI · Oncology | $2,050 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee | $1,330 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| AstraZeneca Pharmaceuticals LP Jul 10, 2025 | Consulting Fee | $1,370 |
| AstraZeneca Pharmaceuticals LP Jul 2, 2025 | Consulting Fee IMFINZI · Oncology | $333 |
| AstraZeneca Pharmaceuticals LP Mar 11, 2025 | Consulting Fee | $2,460 |
| Pfizer Inc. Jan 14, 2025 | Consulting Fee PADCEV · ONCOLOGY | $4,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $147,637 in research payments for these studies, mostly to the institutions running them.
- A phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco
AstraZeneca Pharmaceuticals LP - FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company · Recruiting · NCT05614739 - Phase 1/11 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
AstraZeneca Pharmaceuticals LP - Phase 2 Window of Opportunity Study of INCB054828 in Non-muscle Invasive Bladder Cancer Patients with Recurrent Low- or Intermediate-Risk Tumors
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.